We performed a comprehensive kinase expression analysis using RNA sequencing to explore potential therapeutic targets for IPF and found that DCLK1 and STK33 may serve as potential candidates for molecular targeted therapy of IPF. Here, DCLK1 is linked to idiopathic pulmonary fibrosis.